Praxis Precision Medicines, Inc.
Every calculator, already run for PRAX
Open the full toolkit →You have the numbers on PRAX. Get the argument.
A written report on which of these readings actually decide the outcome for Praxis Precision Medicines, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
19 analysts covering PRAXAnalyst Price Target Disagreement for Praxis Precision Medicines, Inc.
Wall Street's bull case implies +320% from the current price; the bear case implies -34%. A 355% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for PRAX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epile…
PRAX — frequently asked
Is PRAX a buy right now?
Wall Street's consensus rating on Praxis Precision Medicines, Inc. is Strong Buy across 19 analysts, with a mean price target of $638.68 (+124% vs. the current $285.65). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is PRAX's next earnings date?
Praxis Precision Medicines, Inc. is next scheduled to report earnings around Nov 9, 2026. A full PRAX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Praxis Precision Medicines, Inc.?
Analysts covering Praxis Precision Medicines, Inc. (PRAX) range from a bear-case target of $188.00 to a bull-case high of $1,201.00, with a mean consensus target of $638.68 across 19 analysts. The spread of $1,013.00 (355% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Praxis Precision Medicines, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Praxis Precision Medicines, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full PRAX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Praxis Precision Medicines, Inc., in minutes. 3 free reports included with every account — no credit card required.